AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo said on Friday that the European Medicines Agency (EMA) endorsed ENHERTU for the ...
Approval would expand the use of Enhertu to breast cancer patients with nearly undetectable HER2 levels in their tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback